An observational study in Necrotizing Pancreatitis, sponsored by West China Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-01.
Sponsored by West China Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pancreatitis, Acute Necrotizing with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · China.
Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, this one is one of 3 that started in 2025, is one of 3 observational ones, and was the 17th registered.
75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.
Browse Pancreatitis, Acute Necrotizing studies →6 of the 17 studies in Pancreatitis, Acute Necrotizing with a site in China are open now. Recruiting first, the newest first:
Zhejiang University · Sites in China
Ages 18–75
Chunling Jiang · Sites in China
Ages 18+
First People's Hospital of Hangzhou · Sites in China
Ages 18+
Almazov National Medical Research Centre · Sites in China, Russia
Ages 18+
The First Affiliated Hospital of Nanchang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 101 across 26 observational studies indexed under Pancreatitis, Acute Necrotizing.
Median enrollment 135 across the 14 interventional studies, 200 across the 3 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 10 most frequent:
West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.
West China Hospital has 1 study filed under Pancreatitis, Acute Necrotizing — fewer than ten, so there is no comparison to draw.
4 of the studies in Pancreatitis, Acute Necrotizing with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093996Almazov National Medical Research CentreEndoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis | 2026-12-01 |
| NCT07201246West China HospitalOrgan Dysfunction Changes in Acute Necrotizing Pancreatitis Patients With Sepsis Following Open Necrosectomy | 2026-12-30 |
| NCT06380842Chunling JiangOrgan Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy | 2026-12-30 |
| NCT07080697Zhejiang UniversityA Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension | 2027-02-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this retrospective study was to characterize the changes in organ dysfunction among patients with acute necrotizing pancreatitis complicated by sepsis who underwent open necrosectomy.
Baseline demographic and clinical characteristics (including age, gender, and education level) were collected from medical records. Organ dysfunction was defined according to the Sequential Organ Failure Assessment (SOFA) score. SOFA scores were extracted at predefined time points: preoperative (T1), postoperative day 1 (T2), postoperative day 3 (T3), and either postoperative day 7 or hospital discharge, whichever occurred first (T4). Postoperative survival status up to 1 year was obtained from the institutional database.
This retrospective cohort included patients with acute necrotizing pancreatitis complicated by sepsis who underwent open necrosectomy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergo repeat surgery on the same site
SOFA scores at predefined time points were retrospectively extracted from the institutional database in acute necrotizing pancreatitis patients with sepsis who underwent open necrosectomy to characterize organ dysfunction trajectories
Other: Necrotizing Pancreatitis patients' organdysfunction progression
Study the dynamic nature of organ dysfunction
Measure organ dysfunction change after open necrosectomy with respect to time
Organ dysfunction was assessed retrospectively using the Sequential Organ Failure Assessment (SOFA) score, which ranges from 0 (normal) to 4 (most abnormal) for each organ, with higher scores indicating more severe dysfunction.
Time frame: up to postoperative day 7, or at hospital discharge, whichever comes first
Incidence of ICU mortality
Time frame: an average of 1year
Incidence of hospital mortality
Time frame: an average of 1 year
Incidence of 28-day mortality
Time frame: an average of 1 year
Incidence of one year mortality
Time frame: an average of 1 year
ICU length of hospital stay
Time frame: an average of 1 year
Length of hospital stay
Time frame: an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2025; primary completion for Dec 2026, 14 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pancreatitis, Acute Necrotizing →